Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 57, Issue 1, 2011, Pages 56-62

  Champagne, Martin A ^a   Fu, Cecilia H ^b   Chang, Myron ^c   Chen, Helen ^c   Gerbing, Robert B ^c   Alonzo, Todd A ^d,k   Cooley, Linda D ^e   Heerema, Nyla A ^f   Oehler, Vivian ^g   Wood, Charlotte ^c   French, Mary Ellen ^a   Arceci, Robert J ^h   Smith, Franklin O ⁱ   Bernstein, Mark L ^j  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Children's Oncology Group   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^j IWK HEALTH CENTRE   (Canada)

^k CHILDREN S ONCOLOGY GROUP   (United States)

more..

Author keywords

Imatinib therapy; Pediatric chronic myelogenous leukemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; IMATINIB;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADOLESCENT; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; LYMPHOPHENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL RATE;

EID: 79955733477     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23031     Document Type: Article

References (35)

1. Smith MA, Gloeckler Ries LA, Gurney JG, et al. Leukemia in Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995, National Cancer Institute, SEER program. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). 1999; 99-4649: 17-34.
2. Cwynarski K, Roberts IA, Iacobelli S, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003;102:1224-1231.
3. Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339-346.
4. Dini G, Rondelli R, Miano M, et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children: Experience of eight European Countries. The EBMT Paediatric Diseases Working Party. Bone Marrow Transplant 1996;18:80-85.
5. Gamis AS, Haake R, McGlave P, et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 1993;11:834-838.
6. Savage DG, Antman KH. Imatinib mesylate. A new oral targeted therapy. N Engl J Med 2002;346:683-693.
7. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
8. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003;102:83-86.
9. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia. Blood 2004;103:2873-2878.
10. Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754-4759.
11. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655-2660.
12. Peng B, Hayes M, Resta D, et al. Clinical investigation of the pharmacokinetics and pharmacodynamics of imatinib in a phase 1 trial in chronic myeloid leukaemia patients. J Clin Oncol 2004;22:935-942.
13. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002;99:1928-1937.
14. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-3553.
15. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
16. Baccarini M, Dreyling M. and on behalf of the ESMO guidelines working group. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; v165-v167.
17. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer program. Leukemia 2003;17:2318-2357.
18. Saldanha J, Silvy M, Beaufils N, et al. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: Towards new standards for gene expression measurements. Leukemia 2007;21:1481-1487.
19. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:475-481.
21. Deininger MW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647.
22. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-2013.
23. Kantarjian HM, Larson RA, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551-560.
24. Joshi S, Sunita P, Deshmukh C, et al. Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate. Indian J Cancer 2008;45:45-49.
25. Hasserjian RP, Boecklin F, Parker S, et al. STI571 reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002;117:360-367.
26. Frater JL, Tallman MS, Variakojis D, et al. Chronic myeloid leukemia following therapy with imatinib mesylate. Am J Clin Pathol 2003;113:833-841.
27. Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-192.
28. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
29. Hensley ML, Ford JM. Imatinib treatments: Specific issues related to safety, fertility and pregnancy. Semin Hematol 2003;40:21-25.
30. Li B, Boast S, de los Santos K, et al. Mice deficient in ABL are osteoporotic and have defects in osteoblast maturation. Nat Genet 2000;24:304-308.
31. Thornley I, Perentesis JP, Davies SM, et al. Treating children with chronic myeloid leukemia in the imatinib era: A therapeutic dilemma (editorial)? Med Pediatr Oncol 2003;41:115-117.
32. Pulsipher M. Treatment of CML in pediatric patients: Should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer 2004;43:523-533.
33. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006;354:2594-2596.
34. Simonsson B. Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib: Update from the IRIS study. Blood 2006;106:52a (abstract).
35. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007;109:1782-1789.